Antios Raises $96m To Advance HBV Drug With Pharmasset Pedigree

 
• By Joseph Haas
  
Hepatitis B
With $96m, Antios will continue developing ATI-2173 toward functional cure in HBV
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business